Structure Therapeutics Past Earnings Performance
Past criteria checks 0/6
Structure Therapeutics's earnings have been declining at an average annual rate of -35.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-35.4%
Earnings growth rate
49.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -12.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29Revenue & Expenses Breakdown
How Structure Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -111 | 47 | 95 |
| 30 Jun 24 | 0 | -100 | 42 | 80 |
| 31 Mar 24 | 0 | -98 | 37 | 78 |
| 31 Dec 23 | 0 | -90 | 33 | 70 |
| 30 Sep 23 | 0 | -77 | 26 | 58 |
| 30 Jun 23 | 0 | -66 | 21 | 50 |
| 31 Mar 23 | 0 | -58 | 18 | 41 |
| 31 Dec 22 | 0 | -53 | 16 | 36 |
| 30 Sep 22 | 0 | -56 | 15 | 38 |
| 31 Dec 21 | 0 | -44 | 9 | 29 |
Quality Earnings: GPCR is currently unprofitable.
Growing Profit Margin: GPCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GPCR is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare GPCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GPCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: GPCR has a negative Return on Equity (-12.33%), as it is currently unprofitable.